$TBTC
TABLE TRAC INC

2023 Q2 Form 10-Q Financial Statement

#000143774923014053 Filed on May 12, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $2.437M $2.302M
YoY Change -0.91% -31.31%
Cost Of Revenue $566.5K $421.8K
YoY Change -64.64% -36.24%
Gross Profit $1.870M $1.881M
YoY Change 118.18% -30.1%
Gross Profit Margin 76.75% 81.68%
Selling, General & Admin $1.202M $1.544M
YoY Change 6.01% 42.1%
% of Gross Profit 64.25% 82.09%
Research & Development $16.28K $16.28K
YoY Change
% of Gross Profit 0.87% 0.87%
Depreciation & Amortization $0.00 $0.00
YoY Change -100.0% -100.0%
% of Gross Profit 0.0% 0.0%
Operating Expenses $1.202M $1.560M
YoY Change 6.01% 43.6%
Operating Profit $668.6K $336.8K
YoY Change -341.97% -79.0%
Interest Expense $84.15K $88.48K
YoY Change 443.96% 116.28%
% of Operating Profit 12.59% 26.27%
Other Income/Expense, Net $4.280K $0.00
YoY Change -100.0%
Pretax Income $757.0K $425.3K
YoY Change -390.23% -74.31%
Income Tax $185.6K $89.40K
% Of Pretax Income 24.52% 21.02%
Net Earnings $571.4K $335.9K
YoY Change -335.79% -73.38%
Net Earnings / Revenue 23.45% 14.59%
Basic Earnings Per Share $0.13 $0.07
Diluted Earnings Per Share $0.12 $0.07
COMMON SHARES
Basic Shares Outstanding 4.632M 4.622M
Diluted Shares Outstanding 4.618M 4.627M

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.754M $5.282M
YoY Change 7.97% -7.32%
Cash & Equivalents $4.693M $5.219M
Short-Term Investments $60.76K $63.49K
Other Short-Term Assets $753.8K $453.9K
YoY Change 102.09% -55.2%
Inventory $1.805M $1.724M
Prepaid Expenses $753.7K $453.9K
Receivables $1.966M $1.769M
Other Receivables $36.68K $0.00
Total Short-Term Assets $9.316M $9.229M
YoY Change 16.2% -0.77%
LONG-TERM ASSETS
Property, Plant & Equipment $128.7K $143.3K
YoY Change 6415.44% 2808.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $149.2K $161.1K
YoY Change 27.79% 26.72%
Other Assets
YoY Change
Total Long-Term Assets $1.458M $1.399M
YoY Change 19.84% 40.25%
TOTAL ASSETS
Total Short-Term Assets $9.316M $9.229M
Total Long-Term Assets $1.458M $1.399M
Total Assets $10.77M $10.63M
YoY Change 16.68% 3.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $186.4K $429.4K
YoY Change -51.49% 122.37%
Accrued Expenses $123.0K $107.3K
YoY Change 78.7% 79.44%
Deferred Revenue $701.6K $1.078M
YoY Change -24.29% -17.7%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.011M $1.623M
YoY Change -26.72% -30.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $64.89K $81.18K
YoY Change -35.44% -27.74%
Total Long-Term Liabilities $64.89K $81.18K
YoY Change -35.44% -27.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.011M $1.623M
Total Long-Term Liabilities $64.89K $81.18K
Total Liabilities $1.584M $1.992M
YoY Change -3.55% -20.19%
SHAREHOLDERS EQUITY
Retained Earnings $7.159M $6.634M
YoY Change 23.68% 10.01%
Common Stock $2.257M $2.229M
YoY Change 10.75% 11.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.190M $8.637M
YoY Change
Total Liabilities & Shareholders Equity $10.77M $10.63M
YoY Change 16.68% 3.2%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $571.4K $335.9K
YoY Change -335.79% -73.38%
Depreciation, Depletion And Amortization $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Operating Activities -$482.2K $432.0K
YoY Change -62.83% -39.48%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -43.32K
YoY Change
NET CHANGE
Cash From Operating Activities -482.2K $432.0K
Cash From Investing Activities $0.00
Cash From Financing Activities -43.32K
Net Change In Cash -525.5K $432.0K
YoY Change -59.49% -39.48%
FREE CASH FLOW
Cash From Operating Activities -$482.2K $432.0K
Capital Expenditures $0.00
Free Cash Flow $432.0K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Assets Current
AssetsCurrent
9229295 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
8816211 usd
CY2023Q1 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
1094869 usd
CY2022Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
1523793 usd
CY2023Q1 tbtc Salestype Lease Net Investment In Lease After Allowance For Credit Loss Noncurrent
SalestypeLeaseNetInvestmentInLeaseAfterAllowanceForCreditLossNoncurrent
161089 usd
CY2022Q4 tbtc Salestype Lease Net Investment In Lease After Allowance For Credit Loss Noncurrent
SalestypeLeaseNetInvestmentInLeaseAfterAllowanceForCreditLossNoncurrent
176444 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
143294 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
157802 usd
CY2023Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
1399252 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
1858039 usd
CY2023Q1 us-gaap Assets
Assets
10628547 usd
CY2022Q4 us-gaap Assets
Assets
10674250 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
429438 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
417853 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
51052 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10665 usd
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1077698 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1485622 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
56197 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
55942 usd
CY2023Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
8202 usd
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
0 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1622587 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1970082 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
81183 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
97476 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
288000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
331000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
1991770 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2398558 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
4632 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4622 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2224702 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2207030 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
6633500 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
6297639 usd
CY2023Q1 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
8862834 usd
CY2022Q4 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
8509291 usd
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
226057 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
233599 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8636777 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8275692 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10628547 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10674250 usd
CY2023Q1 us-gaap Revenues
Revenues
2302410 usd
CY2022Q1 us-gaap Revenues
Revenues
3351834 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
421841 usd
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
661622 usd
CY2023Q1 us-gaap Gross Profit
GrossProfit
1880569 usd
CY2022Q1 us-gaap Gross Profit
GrossProfit
2690212 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1543786 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1086396 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
336783 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1603816 usd
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
0 usd
CY2022Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
10611 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
88478 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
40913 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
425261 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1655340 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
89400 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
393500 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
335861 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1261840 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4551988
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4521988
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4626930
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4596037
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6527358 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
13707 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1261840 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
7802905 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
8275692 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
25224 usd
CY2023Q1 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
0 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
335861 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
8636777 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
335861 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1261840 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2952 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-43000 usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
72000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
25224 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
13707 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-528445 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
679505 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
163814 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-273928 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
36658 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
213587 usd
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-11041 usd
CY2022Q1 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-9622 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
10056 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-66854 usd
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
40387 usd
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-13685 usd
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-407924 usd
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-266500 usd
CY2023Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-132400 usd
CY2022Q1 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-319950 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
432017 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
713868 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
432017 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
713868 usd
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4756734
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4756734
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4631988
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4621988
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
124746
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
134746
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2273 usd
CY2022 us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
0
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
101500
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-32987
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0336568
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
6101 Baker Road, Suite 206
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Minnetonka
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55345
CY2023Q1 dei City Area Code
CityAreaCode
952
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
548-8877
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4786923 usd
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4631988
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5218940 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4786923 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1768967 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1868488 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
1723989 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1560175 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
453912 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
417254 usd
CY2023Q1 tbtc Salestype Lease Net Investment In Lease After Allowance For Credit Loss Current
SalestypeLeaseNetInvestmentInLeaseAfterAllowanceForCreditLossCurrent
63487 usd
CY2022Q4 tbtc Salestype Lease Net Investment In Lease After Allowance For Credit Loss Current
SalestypeLeaseNetInvestmentInLeaseAfterAllowanceForCreditLossCurrent
59173 usd
CY2023Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
0 usd
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
124198 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4945913 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5218940 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5659781 usd
CY2023Q1 us-gaap Stock Issued1
StockIssued1
7542 usd
CY2022Q1 us-gaap Stock Issued1
StockIssued1
0 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
14508 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
15340 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><span style="text-decoration: underline; ">Use of Estimates</span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s use of estimates and assumptions include: for revenue recognition, determining collectibility, the nature and timing of satisfaction of performance obligations, and determining the standalone selling price (“SSP”) of performance obligations, realizability of accounts receivable, and the valuation of allowance for credit losses, deferred tax assets and liabilities, and inventory. Actual results could differ from those estimates, and the difference could be significant.  For further information about our critical accounting estimates, see the discussion in Item <em style="font: inherit;">7,</em> “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” under the heading “Critical Accounting Policies and Estimates” in the Company’s Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2022.</em></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">There were <em style="font: inherit;">no</em> changes in critical accounting estimates or assumptions for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2023</em>.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;">The Company’s significant accounting policies are described in Note <em style="font: inherit;">1</em> of the financial statement included in its Annual Report on Form <em style="font: inherit;">10</em>-K for the year ended <em style="font: inherit;"> December 31, 2022</em>.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">Concentrations of Risk</span></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The Company maintains its cash balances at <em style="font: inherit;">two</em> financial institutions. Accounts are insured by the Federal Deposit Insurance Corporation (FDIC) up to <em style="font: inherit;">$250,000</em><span style="background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">. At times throughout the year, </span>the Company’s cash balances exceeded amounts insured by the FDIC. The Company doesn’t believe it is exposed to any significant credit risk on its cash balances.  Cash equivalents represent money market funds or short-term investments with original maturities of <em style="font: inherit;">three</em> months or less from the date of purchase.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"> </p>
CY2023Q1 tbtc Salestype Lease Net Investment In Lease After Allowance For Credit Loss Current
SalestypeLeaseNetInvestmentInLeaseAfterAllowanceForCreditLossCurrent
63487 usd
CY2023Q1 us-gaap Revenues
Revenues
2302410 usd
CY2022Q1 us-gaap Revenues
Revenues
3351834 usd
CY2023Q1 tbtc Percent Of Revenues
PercentOfRevenues
1.000 pure
CY2022Q1 tbtc Percent Of Revenues
PercentOfRevenues
1.000 pure
CY2023Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
0 usd
CY2022Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
65000 usd
CY2023Q1 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
2682300 usd
CY2022Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss
ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss
2781800 usd
CY2022Q4 tbtc Salestype Lease Net Investment In Lease After Allowance For Credit Loss Current
SalestypeLeaseNetInvestmentInLeaseAfterAllowanceForCreditLossCurrent
59173 usd
CY2023Q1 tbtc Salestype Lease Net Investment In Lease After Allowance For Credit Loss Noncurrent
SalestypeLeaseNetInvestmentInLeaseAfterAllowanceForCreditLossNoncurrent
161089 usd
CY2023Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2273 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
1560175 usd
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
208718 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
396880 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16275 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2022Q4 tbtc Salestype Lease Net Investment In Lease After Allowance For Credit Loss Noncurrent
SalestypeLeaseNetInvestmentInLeaseAfterAllowanceForCreditLossNoncurrent
176444 usd
CY2022Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.05 pure
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
14508 usd
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
15340 usd
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.52
CY2023Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1846397 usd
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
1930488 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
77430 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
62000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1768967 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1868488 usd
CY2023Q1 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
1094869 usd
CY2022Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
1523793 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
62000 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
15430 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
-0 usd
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
77430 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Remainder Of Fiscal Year
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedRemainderOfFiscalYear
53775 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
71700 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
71700 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
26875 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Four Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedFourYears
22800 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
246850 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable Undiscounted Excess Amount
SalesTypeAndDirectFinancingLeasesLeaseReceivableUndiscountedExcessAmount
22274 usd
CY2023Q1 us-gaap Sales Type And Direct Financing Leases Lease Receivable
SalesTypeAndDirectFinancingLeasesLeaseReceivable
224576 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
48626 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
65683 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
35445 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
149754 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
12374 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
137380 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M13D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
70000
CY2021Q2 tbtc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue
128726 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
15000
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
22919 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
16500
CY2022Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
37969 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M21D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.97
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
151800 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
76500
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.15
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
104500 usd
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
101500
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.97
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
85000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
101500
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.97
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
85000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.52
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
76500
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.15
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
32500
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.52
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
335861 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1261840 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4551988
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4521988
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.28
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4626930
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4596037
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.27
CY2023Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
74942
CY2022Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
74049

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001437749-23-014053-index-headers.html Edgar Link pending
0001437749-23-014053-index.html Edgar Link pending
0001437749-23-014053.txt Edgar Link pending
0001437749-23-014053-xbrl.zip Edgar Link pending
ex_499252.htm Edgar Link pending
ex_499253.htm Edgar Link pending
ex_499254.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tbltrc20230331_10q.htm Edgar Link pending
tbltrc20230331_10q_htm.xml Edgar Link completed
tbtc-20230331.xsd Edgar Link pending
tbtc-20230331_def.xml Edgar Link unprocessable
tbtc-20230331_cal.xml Edgar Link unprocessable
tbtc-20230331_lab.xml Edgar Link unprocessable
tbtc-20230331_pre.xml Edgar Link unprocessable